University cancer research centre gets planning approval

The University of Southampton's planning application to build the Centre for Cancer Immunology has been approved by Southampton City Council.

The Centre will be based at Southampton General Hospital and bring together world leading cancer scientists to expand interdisciplinary research teams, increase the number of clinical trials and develop lifesaving drugs.

The Centre will be the first of its kind in the UK and boast state-of-the-art laboratories, patient facilities and office space.

Professor Tim Elliott, Director of the Centre for Cancer Immunology, commented: "We are delighted to receive planning permission for the new Centre. We hope to start work as soon as possible. We will be working with the hospital to ensure there is minimal disruption to patients, visitors and staff on the hospital site and hope to have the building completed in 2017."

The new Centre will be built opposite the hospital's main entrance, next to the Somers Building, replacing the disabled car parking spaces. These spaces are being relocated throughout the hospital site at access points including the main entrance (with spaces on the ground floor of the main car park), the eye unit, the neurological centre, the west wing entrance and Taplins nursery. Additional standard parking spaces, sufficient to cover the spaces taken over by the disabled spaces, will be made available in the new multistorey car park, in Coxford Road.

The University of Southampton launched a campaign last year to raise £25 million to fund the new Centre and is has reached 75 per cent of the target. One such donor is Matthew Hodgson of Warwick Capital Partners LLP.

"The creation of a world-leading Centre will not only reinforce collaboration and exchange of ideas but it will also attract the greatest minds in the field," he said.

Immunotherapy is a revolutionary new treatment, supercharging the body's natural defences to find and destroy cancer.

The new treatments being developed by Southampton scientists, in the form of vaccines and antibodies, direct special immune cells against cancers. These 'killer' cells can control and shrink cancer and give long-lasting protection. The University has developed treatments to target some of the most aggressive forms of the disease including cancers of the lung and skin,

and childhood neuroblastoma. Results from clinical trials are very promising with more than 20 per cent of participants living cancer free.

Professor Elliott said: "The University has a long-standing track in innovative immunology research with a strong and successful 'bench to bedside' approach. This new Centre will enhance our expertise and expand the research teams in Southampton to make even greater progress in developing new treatments. The next few years will see great advances in immune therapies for cancer with the University of Southampton at the very forefront of discovery."

ENDS

Notes to editors

- 1. Photo attached is an architect's impression of the new Centre for Cancer Immunology. Please credit University of Southampton.
- 2. More information about the University's campaign for the new Centre can be found at www.southampton.ac.uk/youreit along with more information about the plans for the new building.
- 3. Examples of patients who have already benefited from cancer immunotherapy are available from Media Relations upon request.
- 4. Through world-leading research and enterprise activities, the University of Southampton connects with businesses to create realworld solutions to global issues. Through its educational offering, it works with partners around the world to offer relevant, flexible education, which trains students for jobs not even thought of. This connectivity is what sets Southampton apart from the rest; we make connections and change the world. http://www.southampton.ac.uk/ http://www.southampton.ac.uk/weareconnected #weareconnected

For more information:

Becky Attwood, Media Relations Officer, Tel: 02380 592128, Mob:

07342060429, Email: r.attwood@soton.ac.uk